Comparing the current results to its competitors, Novavax Inc reported Revenue decrease in the 2 quarter 2026 year on year by -76.3 %, despite the revenue increase by the most of its competitors of 6.37 %, recorded in the same quarter.
Novavax inc , slower than the average decrease reported by the company's competitors of -77.86 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -77.86 %
Novavax Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment with several competitors possessing greater resources and experience, which may affect its commercial opportunities. Competitors are developing new products and updated versions of existing products, often incorporating adjuvants to enhance immunogenicity. Several competitors are also working on seasonal influenza vaccines using various technologies, including mRNA technology. Notably, Moderna and Pfizer are identified as key competitors in this area. Moderna is developing a COVID-19-influenza combination vaccine candidate and is engaged with the U.S. FDA for regulatory approval and commercialization. The company's competitive position is influenced by factors such as product efficacy, safety, reliability, availability, pricing, patent status, development speed, clinical trial outcomes, regulatory approvals, manufacturing capabilities, and the ability to attract qualified personnel and secure capital.
Calidi Biotherapeutics Inc's business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.
Apogee Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative therapies for various medical conditions. Their business model revolves around conducting extensive research to identify potential drug candidates, and then advancing them through preclinical and clinical trials to secure regulatory approvals. By licensing or partnering with larger pharmaceutical companies, Apogee Therapeutics aims to bring these drugs to market and improve patient outcomes.
In8bio Inc operates as a clinical-stage biotechnology company that focuses on developing transformative therapies for the treatment of cancer and other diseases. The company follows a research and development model centered on leveraging their proprietary platform to identify and optimize novel genetic circuits for targeted cell-based therapies.
Sources:
Novavax inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Novavax inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
